Intersect Ent Inc (NASDAQ:XENT) Sellers Rose By 6.78% Their Shorts

June 29, 2018 - By Gregory Tomko

Intersect ENT, Inc. (NASDAQ:XENT) Corporate Logo

It was recorded an increase on Intersect Ent Inc (NASDAQ:XENT)’s shares shorted with 6.78%. It was announced in June by FINRA the 305,400 shares shorted on XENT. That’s 6.78% up from 286,000 shares. With Average volume 193,600, XENT’s former position will take 2 days to recover. Intersect Ent Inc’s shares shorted float is 1.14%.

XENT touched $37.45 during the last trading session after $0.45 change.Currently Intersect ENT, Inc. is uptrending after 64.79% change in last June 29, 2017. XENT has also 87,979 shares volume. The stock outperformed the S&P500 by 52.22%.

Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States.The company has $1.13 billion market cap. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.Currently it has negative earnings. The firm is also developing RESOLVE, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting.

Intersect ENT, Inc. (NASDAQ:XENT) Ratings Coverage

In total 3 analysts cover Intersect ENT (NASDAQ:XENT). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. (NASDAQ:XENT) has 100% bullish analysts. 4 are the (NASDAQ:XENT)’s ratings reports on Jun 29, 2018 according to StockzIntelligence Inc. On Monday, May 7 Canaccord Genuity maintained Intersect ENT, Inc. (NASDAQ:XENT) rating. Canaccord Genuity has “Buy” rating and $4600 target. On Wednesday, May 2 the stock of Intersect ENT, Inc. (NASDAQ:XENT) has “Buy” rating given by J.P. Morgan. In Tuesday, January 2 report JP Morgan upgraded the stock to “Overweight” rating. On Thursday, January 4 the company was maintained by Canaccord Genuity.

Another two news for Intersect ENT, Inc. (NASDAQ:XENT) were recently published by: Fool.com on June 01, 2018 with title “3 Top Healthcare Stocks to Buy Right Now”. The other Prnewswire.com‘s article was titled “Faruqi & Faruqi, LLP is Investigating Intersect ENT, Inc. (XENT) on Behalf of its Shareholders” and published on June 18, 2018.

Intersect ENT, Inc. (NASDAQ:XENT) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.